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Abstract
Objective:  To  characterize  the  hearing  loss  after  cancer  treatment,  according  to  the  type  of
treatment,  with  identiﬁcation  of  predictive  factors.
Methods:  Two  hundred  patients  who  had  cancer  in  childhood  were  prospectively  evaluated.  The
mean age  at  diagnosis  was  6  years,  and  at  the  audiometric  assessment,  21  years.  The  treat-
ment of  the  participants  included  chemotherapy  without  using  platinum  derivatives  or  head
and neck  radiotherapy  in  51  patients;  chemotherapy  using  cisplatin  without  radiotherapy  in
64 patients;  head  and  neck  radiotherapy  without  cisplatin  in  75  patients;  and  a  combined  treat-
ment of  head  and  neck  radiotherapy  and  chemotherapy  with  cisplatin  in  ten  patients.  Patients
underwent  audiological  assessment,  including  pure  tone  audiometry,  speech  audiometry,  and
immittancemetry.
Results: The  treatment  involving  chemotherapy  with  cisplatin  caused  41.9%  and  47.3%  hearing
loss in  the  right  and  left  ear,  respectively,  with  a  11.7-fold  higher  risk  of  hearing  loss  in  the
right ear  and  17.6-fold  higher  in  the  left  ear  versus  patients  not  treated  with  cisplatin  (p  <  0.001
and p  <  0.001,  respectively).  Children  whose  cancer  diagnosis  occurred  after  the  age  of  6  have
shown an  increased  risk  of  hearing  loss  vs.  children  whose  diagnosis  occurred  under  6  years  of
age (p  =  0.02).
 Please cite this article as: Liberman PH, Gofﬁ-Gomez MV, Schultz C, Novaes PE, Lopes LF. Audiological proﬁle of patients treated for
childhood cancer. Braz J Otorhinolaryngol. 2016;82:623--9.
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Conclusion:  The  auditory  feature  found  after  the  cancer  treatment  was  a  symmetrical  bilateral
sensorineural  hearing  loss.  Chemotherapy  with  cisplatin  proved  to  be  a  risk  factor,  while  head
and neck  radiotherapy  was  not  critical  for  the  occurrence  of  hearing  loss.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Perﬁl  audiológico  de  pacientes  tratados  de  câncer  na  infância
Resumo
Objetivo:  Caracterizar  as  alterac¸ões  auditivas  após  o  tratamento  do  câncer,  segundo  o  tipo  de
tratamento  identiﬁcando  os  fatores  preditivos.
Método:  Foram  avaliados  prospectivamente  duzentos  pacientes  que  tiveram  cancer  na  infân-
cia. A  idade  média  ao  diagnóstico  foi  de  6  anos  e  à  avaliac¸ão  audiométrica  de  21  anos  de
idade. O  tratamento  incluiu  quimioterapia  sem  uso  de  derivados  de  platina  ou  radioterapia  em
cabec¸a e  pescoc¸o  em  51  pacientes;  quimioterapia  com  uso  de  cisplatina  sem  radioterapia  em
64 pacientes;  radioterapia  em  cabec¸a  e  pescoc¸o  sem  cisplatina  em  75  pacientes;  e  10  pacientes
receberam  o  tratamento  combinado  de  radioterapia  em  cabec¸a  e  pescoc¸o  e  quimioterapia  com
cisplatina.  Os  pacientes  foram  submetidos  à  avaliac¸ão  audiológica  incluindo  audiometria  tonal,
audiometria  vocal  e  imitanciometria.
Resultados:  O  tratamento  envolvendo  quimioterapia  com  cisplatina  levou  a  41,9%  e  47,3%  de
perda auditiva  na  orelha  direita  e  esquerda,  respectivamente,  apresentando  risco  11,7  vezes
maior de  desenvolver  perda  auditiva  na  orelha  direita  e  17,6  vezes  na  orelha  esquerda  do  que
aqueles  que  não  receberam  cisplatina  (p  <  0,001  e  p  <  0,001;  respectivamente).  Crianc¸as  cujo
diagnóstico  do  câncer  ocorreu  após  os  6  anos  de  idade  mostraram  maior  risco  de  apresentar
perda auditiva  do  que  crianc¸as  menores  do  que  6  anos  de  idade  (p  =  0,02).
Conclusão:  A  característica  audiológica  encontrada  após  tratamento  oncológico  foi  perda  audi-
tiva sensorioneural  bilateral  simétrica.  A  quimioterapia  com  cisplatina  mostrou  ser  fator  de
risco, enquanto  a  radioterapia  em  cabec¸a  e  pescoc¸o  não  foi  determinante  para  aquisic¸ão  da
perda auditiva.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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ver  the  last  two  decades,  childhood  cancer  mortality  has
ecreased  signiﬁcantly;  however,  it  still  represents  the  sec-
nd  leading  cause  of  death  in  Brazil.1 Currently,  with  the
dvances  in  diagnosis,  improved  treatments,  and  appro-
riate  clinical  support,  an  increase  in  the  cure  rate  of
alignancies  in  childhood  is  a  possibility.2 In  the  face  of  an
ncreasing  survival  rate,  these  individuals  are  now  monitored
or  several  years.  Thus,  it  is  possible  to  observe  the  impact
f  late  effects  of  treatment  on  the  quality  of  life  of  these
oung  adults.
The  use  of  different  treatment  modalities  (surgery,  radio-
herapy,  and  chemotherapy)  and  the  combination  of  these
odalities  contribute  to  improved  results,  both  in  control-
ing  the  disease  and  in  improving  survival  rates.3
Among  the  ototoxic  drugs,  cisplatin  is  an  antineoplastic
gent  with  proven  anti-tumor  activity,  but  which  may  have
totoxicity  as  a  side  effect;  the  dose  related  to  risk  has  been
escribed  as  being  400  mg/m2.2,4,5Head  and  neck  radiotherapy  concomitantly  employed
ith  cisplatin  (cis-diamminedichloroplatinum  [CDDP])
ncreases  the  likelihood  of  severe  hearing  loss.6,7 However,
W
b
fhen  the  drug  is  administered  alone  and  in  lower  doses
50--60  Gy),  no  clinically  signiﬁcant  hearing  loss  occurs.8,9
Ototoxicity,  i.e., the  effect  represented  by  an  injury
o  the  peripheral  organ  of  hearing,  is  characterized  by
n  irreversible  descending  bilateral  sensorineural  hearing
oss.10,11 The  incidence  of  the  hearing  loss  is  quite  variable,
ue  to  the  method  of  drug  administration,  tumor  location,
tate  of  renal  function,  patient’s  age,  associated  drugs,
adiotherapy,  pre-existing  hearing  loss,  cumulative  dose,
otal  dose  of  treatment,  and  individual  susceptibility.12,13
This  study  was  conducted  with  the  aim  of  characterizing
he  audiologic  proﬁle  of  patients  who  had  cancer  in  child-
ood  and  were  out  of  cancer  treatment  for  at  least  eight
ears;  to  relate  the  hearing  loss  found  with  respect  to  the
ype  of  treatment  and  age;  and  to  identify  predictive  factors
or  hearing  loss.
ethodse  prospectively  evaluated  children  who  had  cancer  treated
etween  2000  and  2004,  and  who  had  completed  treatment
or  at  least  eight  years,  and  who  had  been  monitored  in  a
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group  of  pediatric  studies  on  the  late  effects  of  cancer  treat-
ment.  Patients  with  history  of  previous  otologic  disease  or
who  had  been  submitted  to  a  surgery  involving  the  audi-
tory  system  were  excluded.  The  study  was  approved  by  the
Research  Ethics  Committee  of  the  institution  under  the  pro-
tocol  549/03.  Eligible  patients  or  their  legal  guardians  were
consulted  on  the  possibility  of  participating  in  the  study,  and
were  asked  to  sign  the  informed  consent.
Patients  were  interviewed  at  the  Pediatric  Outpatient
Clinic  in  order  to  investigate  the  presence  of  hearing  com-
plaints  and  then  were  referred  to  a  hearing  evaluation  in  the
institution’s  Audiology  Service,  regardless  of  the  presence
of  hearing  complaints.  Otoscopy  was  conducted  before  the
test  and,  if  the  patient  had  cerumen  or  any  suspicion  and/or
obstruction  that  prevented  the  test,  he/she  was  referred  to
the  otorhinolaryngologist  before  evaluation.
For  hearing  assessment,  auditory  quantiﬁcation  tests
(pure  tone  audiometry  and  speech  audiometry)  and
evaluation  tests  of  the  tympanic-ossicular  system  (immit-
tancemetry)  were  performed.  To  this  end,  a  Madsen  Orbiter
922  audiometer  and  a  Madsen  Zodiac  901  immittancemeter
were  used.
The  dose  of  CDDP  received  by  the  participants  was  cal-
culated  and  adjusted  by  the  pediatric  oncologist  for  a body
surface  area  of  1  m2.  The  clinical  records  of  all  patients
who  underwent  head  and  neck  radiotherapy  were  analyzed,
taking  into  account  the  side  on  which  radiotherapy  was  per-
formed  and  whether  the  auditory  system  was  included  in
the  radiation  ﬁeld.  The  total  dose  and  the  estimated  dose
of  radiation  reaching  the  auditory  system  were  calculated
for  each  ear  by  a  radiation  oncologist,  based  on  the  plan-
ning  form.  The  variable  ‘‘radiation  reaching  the  auditory
system’’  was  categorized  as:  no  Rxt,  Rxt  ≤  4000  cGy,  and
Rxt  >  4000  cGy.9,14
Patients  were  studied  according  to  the  type  of  treatment
performed,  based  on  the  use  of  chemotherapy  with  CDDP  or
head  and  neck  radiation  therapy.
Hearing  loss  criteria  were  based  on  the  Bureau  Interna-
tional  d’Audiophonologie  --  BIAP,15 which  considers  hearing
w
r
c
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Table  1  Distribution  of  patients,  according  to  the  type  of  primary  c
Malignant  neoplasm  w/o  Rxt  w/o  CDDP  CDD
n (%)  n  (%
Bone  tumor  8  (15.7)  39  (
Leukemias 1  (2.0)  0  (
Lymphomas  (NHL,  HL)  14  (27.5)  0  (
Retinoblastoma  8  (15.7)  1  (
Germ cell  tumor  2  (3.9)  12  (
Kidney tumors  12  (23.5)  1  (
Soft tissue  sarcomas  3  (5.8)  3  (
CNS tumor  0  (0.0)  0  (
SNS tumor  (neuroblastoma) 1  (2.0)  4  (
Unspeciﬁed 0  (0.0) 1  (
Carcinomas  2  (3.9)  1  (
Liver tumors 0  (0.0) 2  (
Total 51  (100)  64  (
CNS, central nervous system; SNS, sympathetic nervous system; CDDP, 
Hodgkin’s lymphoma.625
oss  as  the  presence  of  pure  tone  thresholds  >20  dB  in
.5--4  kHz  frequencies.
tatistical  analysis
o  identify  hearing  loss  predictors,  a  dichotomous  variable
yes/no)  was  created,  and  hearing  loss  was  diagnosed  only
n  light  of  changes  in  the  frequencies  from  0.25  to  4  kHz.
earing  loss  at  6  and  8  kHz  was  not  included  in  the  statistical
nalysis,  due  to  the  minor  handicap  that  these  losses  cause
n  daily  life.16,17
The  variable  ‘‘age  at  diagnosis’’  was  categorized  as  ≤6
ears  and  >6  years,  based  on  the  median  of  the  values  found.
Measures  of  central  tendency  and  of  dispersion  for  quan-
itative  variables  and  absolute  and  relative  frequencies  for
ategorical  variables  were  calculated.  In  order  to  verify  the
ssociation  among  independent  variables  and  hearing  loss,
he  associative  chi-squared  test  or  Fisher’s  exact  test  (when
t  least  one  of  the  expected  frequencies  was  <5)  was  used.
o  identify  independent  risk  factors  for  occurrence  of  hear-
ng  loss,  logistic  regression  (with  raw  and  adjusted  odds
atios  and  their  respective  95%  conﬁdence  intervals)  was
sed.  For  all  statistical  tests,  an  error  ˛  =  5%  was  established,
.e.,  the  results  were  considered  statistically  signiﬁcant  at
 <  0.05.
esults
he  selected  sample  included  200  patients  treated  for  child-
ood  cancer,  who  were  out  of  treatment  during  the  study
eriod.  Table  1  shows  the  distribution  according  to  the  pri-
ary  tumor  and  the  type  of  treatment  used.  In  this  study,  51
articipants  did  not  undergo  head  and  neck  radiotherapy  and
ere  not  medicated  with  CDDP,  64  received  chemotherapy
ith  CDDP  and  did  not  undergo  head  and  neck  radiothe-
apy,  75  underwent  head  and  neck  radiotherapy  without
hemotherapy  with  CDDP,  and  ten  patients  underwent  head
nd  neck  radiotherapy  and  chemotherapy  with  CDDP.  In  most
ancer  at  diagnosis  and  treatment  type  (GEPETTO  2000--2004).
P  Rxt  Rxt  +  CDDP  Total
)  n  (%)  n  (%)  n  (%)
60.9)  1  (1.3)  0  (0.0)  48  (24.0)
0.0)  43  (57.3)  0  (0.0)  44  (22.0)
0.0)  10  (13.3)  0  (0.0)  24  (12.0)
1.6)  10  (13.3)  5  (50.0)  24  (12.0)
18.7)  0  (0.0)  0  (0.0)  14  (7.0)
1.6)  0  (0.0)  0  (0.0)  13  (6.5)
4.6)  3  (4.0)  2  (20.0)  11  (5.5)
0.0)  4  (5.3)  2  (20.0)  6  (3.0)
6.3)  0  (0.0)  1  (10.0)  6  (3.0)
1.6)  4  (5.3)  0  (0.0)  5  (2.5)
1.6)  0  (0.0)  0  (0.0)  3  (1.5)
3.1)  0  (0.0)  0  (0.0)  2  (1.0)
100)  75  (100)  10  (100)  200  (100)
cisplatin; Rxt, radiotherapy; NHL, non-Hodgkin’s lymphoma; HL,
626  Liberman  PH  et  al.
Table  2  Means  and  standard  deviations  of  the  radiation  dosage  (Rxt)  and  of  cisplatin  (CDDP)  used  according  to  the  type  of
treatment for  the  right  (RE)  and  left  (LE)  ear  (GEPETTO  2000--2004).
Type  of  treatment  n  Rxt  total  dose  (cGy)  RE  Rxt  dose  (cGy)  LE  Rxt  dose  (cGy)  CDDP  dose  (mg/m2)
w/o  Rxt,  w/o  CDDP  51  --  --  --  --
CDDP 64  --  --  --  647.4  ±  326.5
Rxt 75  2996.8  ±  1427.8  1894.8  ±  1544.3  1821.5  ±  1540.8  --
Rxt +  CDDP  10  4214.0  ±  678.9  2292.0  ±  1744.2  1524.0  ±  1692.7  668.1  ±  260.7
Table  3  Distribution  of  patients  who  met  the  hearing  loss  criteria  in  relation  to  the  factors  studied:  sex,  age,  radiation,  and
chemotherapy  with  CDDP  (GEPETTO  2000--2004).
RE  Total  pa LE  Total  pa
w/o  loss
n  (%)
With  loss
n  (%)
n  w/o  loss
n  (%)
With  loss
n  (%)
n
Gender  0.525 0.062
Male 86  (82.7) 18  (17.3) 104  88  (84.6) 16  (15.4) 104
Female 76  (79.2)  20  (20.8)  96  71  (74.0)  25  (26.0)  96
Age 0.001  0.001
≤6 years  100  (90.1)  11  (9.9)  111  98  (88.3)  13  (11.7)  105
>6 years  62  (69.7)  27  (30.3)  89  61  (68.5)  28  (31.5)  95
Rxt 0.025  0.020
w/o Rxt  103  (76.9)  31  (23.1)  134  103  (74.6)  35  (25.4)  138
≤4000 cGy  52  (92.9)  4  (7.1)  56  50  (92.6)  4  (7.4)  54
>4000 cGy  7  (70.0)  3  (30.0)  10  6  (75.0)  2  (25.0)  8
Chemo <0.001  <0.001
w/o CDDP  119  (94.4)  7  (5.6)  126  120  (95.2)  6  (4.8)  126
With CDDP 43  (58.1)  31  (41.9)  74  39  (52.7)  35  (47.3)  74
Total 162  (81.0)  38  (19.0)  200  159  (79.5)  41  (20.5)  200
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Figure  1  Mean  audiometric  conﬁguration  of  hearing  thresh-
olds by  type  of  treatment.  CDDP,  cisplatin;  Rxt,  radiation
t
s
e
lBolded p refer to statistical signiﬁcance (p < 0,05).
a Statistics according to the chi-squared test.
ases,  children  treated  by  Rxt  without  CDDP  had  a  diagnosis
f  leukemia  or  retinoblastoma  and  were  treated  with  mega-
oltage  radiation.  For  patients  who  received  CDDP  +  Rxt,
he  total  radiation  dose  was  higher  (4214.0  ±  678.9  cGy)
s.  patients  who  received  only  Rxt  (2996.8  ±  1427.8  cGy)
Table  2).
Table  3  shows  that  104  (52%)  participants  of  the  sample
ere  male  and  96  (48%)  were  female.
earing loss characterization
atients  who  received  CDDP  or  CDDP  +  Rxt  were  affected  by
 symmetrical  bilateral  sensorineural  hearing  loss  at  4-,  6-,
nd  8-kHz  frequencies.  Hearing  loss  did  not  occur  in  cancer
atients  who  did  not  receive  a  risk-to-hearing  treatment  or
ead  and  neck  Rxt  as  a  single  treatment  (Fig.  1).
dentiﬁcation of predictive factors for hearing
ossn  the  comparison  among  the  three  groups  without  Rxt,  and
ith  Rxt  up  to  4000  or  above  4000  cGy,  both  to  the  right
p  = 0.025)  and  to  the  left  (p  =  0.020)  side,  a  statistically
c
r
t
areatment;  RE,  right  ear;  LE,  left  ear.
igniﬁcant  difference  was  observed.  It  is  not  possible,  how-
ver,  to  state  that  the  Rxt  factor  has  inﬂuenced  the  hearing
oss  because,  the  values  for  the  percentage  of  hearing  loss
omparing  the  group  that  did  not  receive  Rxt  vs.  those  that
eceived  more  than  4000  cGy  are  similar.  Thus,  it  is  believed
hat  the  statistical  signiﬁcance  is  due  to  the  lower  percent-
ge  of  hearing  loss  in  the  group  that  received  less  than
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Table  4  Multiple  analysis  of  predictive  factors  of  hearing  loss  in  the  right  (RE)  and  left  (LE)  ear.
Ear  Variables  Categories  Raw  OR  Adjusted  OR  95%  CI  adjusted  OR  p
RE CDDP No  1.0  1.0  Reference
Yes 12.2  11.7  4.2;  32.1  <0.001a
Rxt w/o  Rxt  1.0  1.0  Reference
≤4000  cGy  0.3  0.9  0.2;  3.3  0.894
>4000 cGy  1.4  4.3  0.8;  24.1  0.196
Age (years) ≤6  1.0  1.0  Reference
>6 3.9 2.7 1.1;  6.4 0.028
LE CDDP No 1.0 1.0 Reference
Yes 17.9 17.6 6.0;  51.4 <0.001b
Rxt w/o  Rxt  1.0  1.0  Reference
≤4000  cGy  0.2  0.9  0.2;  3.4  0.912
>4000 cGy  0.9  3.9  0.5;  31.2  0.192
Age (years) ≤6  1.0  1.0  Reference
>6 3.5 2.1 0.9;  5.0 0.084
OR, odds ratio; CDDP, cisplatin; Rxt, radiotherapy.
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b Hosmer--Lemeshow test (p = 0.459).
4000  cGy,  thereby  differing  from  the  other  two  groups,  as
can  be  seen  in  Table  3.
Multivariate analysis of predictive factors for
hearing loss
In  the  multivariate  analysis  (considering  those  patients  who
did  not  use  CDDP  as  a  control  group),  use  of  CDDP  and
age  at  the  time  of  diagnosis  were  predictive  factors  for
hearing  loss.  Children  whose  treatment  included  the  use  of
CDDP  showed  an  11.7-fold  increased  risk  for  hearing  loss  in
the  right  ear  and  a  17.6-fold  increased  risk  in  the  left  ear
(p  <  0.001  for  both  ears),  compared  to  children  who  did  not
use  CDDP.  Diagnosis  before  the  age  of  6  years  imparted  a  2.7
times  higher  risk  for  hearing  loss  in  the  right  ear  (p  = 0.02),
compared  with  children  aged  ≤6  years  (Table  4).
In  the  multivariate  analysis,  the  dose  of  radiotherapy  was
not  a  risk  factor  for  hearing  loss  when  patients  who  did  not
receive  Rxt  were  used  as  a  control  group.
Discussion
This  study  aimed  to  establish  a  relationship  of  hearing
changes  found  by  type  of  treatment  and  age,  and  to  iden-
tify  predictive  factors  of  hearing  loss  in  patients  who  had
cancer  in  childhood  and  had  completed  cancer  treatment
several  years  before.  To  deﬁne  which  treatment  implied  risk
of  hearing  loss,  a  separation  was  required  between  the  ears,
considering  that  the  incidence  of  radiation  varied  with  the
tumor  site.
This  study  found  a  predominance  of  exams  with  thresh-
olds  within  the  normal  range  in  patients  who  did  not  undergo
treatment  with  CDDP.  Conversely,  patients  who  used  CDDP
or  CDDP  +  Rxt  showed  a  predominance  of  bilateral  sym-
metrical  sensorineural  hearing  loss  at  4-,  6-,  and  8-kHz
frequencies.11,12,18--22 It  is  possible  to  infer  that  hearing  loss
is  related  to  the  type  of  cancer  treatment,  even  considering
that  these  are  individuals  assessed  many  years  after  the  end
u
p
b
4f  their  therapy,  since  the  group  whose  treatment  did  not
nvolve  CDDP  or  Rxt,  under  the  same  conditions,  showed  no
earing  loss.
Paulino  et  al.,23 Johannesen  et  al.,24 Low  et  al.,8 and
ell’Aringa  et  al.9 reported  that  doses  between  4000  and
000  cGy  were  risk  dosages  for  hearing  loss,  and  suggested
udiological  monitoring.  Treatment  with  Rxt  in  head  and
eck  tumors  can  cause  other  ear  disorders  such  as  oti-
is  externa,  serous  otitis  media,25 necrosis  of  the  external
uditory  canal,  and  osteoradionecrosis  of  the  temporal
one.14,24,26 In  the  present  series,  leukemias  were  preva-
ent  in  patients  who  were  treated  with  Rxt  without  CDDP,
nd  these  individuals  showed  no  hearing  loss,  which  is  con-
istent  with  the  results  reported  in  the  study  by  Thibadoux
t  al.27 Indeed,  the  dosage  of  radiation  penetrating  the  right
2292.0  ±  1744.2  cGy)  and  the  left  (1524.0  ±  1692.7  cGy)  ear
as  of  low-risk  for  all  patients  who  underwent  Rxt.  Table  3
hows  that  92.9%  of  patients  who  received  doses  of  radiation
herapy  below  4000  cGy  did  not  show  hearing  loss,  justify-
ng  the  signiﬁcant  association.  In  the  multivariate  analysis  of
redictive  factors  for  hearing  loss,  Rxt  was  not  a risk  factor
or  hearing  loss  (Table  4).
Patients  treated  with  CDDP  and  CDDP  +  Rxt  received  high
oses  of  CDDP  --  higher  than  the  dose  considered  a  risk
or  hearing  loss  (≥400  mg/m2).  In  this  series,  the  mean
ose  of  CDDP  in  patients  treated  with  chemotherapy  was
50  mg/m2, and  in  individuals  who  received  CDDP  +  Rxt,  the
ose  was  670  mg/m2.  Li  et  al.22 pointed  out  the  relation-
hip  between  dose  of  CDDP  and  hearing  loss,  with  dosages
400  mg/m2 showing  a  higher  risk  for  hearing  loss.  Stud-
es  using  conventional  frequencies  (0.25--8  kHz)  for  hearing
valuation  reveal  a  variation  of  20--70%  in  the  incidence  of
earing  loss.28 This  change  occurs  due  to  several  factors,
ncluding:  the  assessed  frequencies,  age  of  the  individ-
als,  dosage  of  CDDP,  drug  dosing  schedule,  and  criteria
sed  to  deﬁne  hearing  loss.  The  present  study  found  a
revalence  of  41.9%  and  47.3%  for  RE  and  LE,  respectively,
ased  on  hearing  loss  criteria  at  frequencies  from  0.25  to
 kHz.
6l
e
r
y
h
≤
a
m
l
e
t
g
c
b
y
t
o
c
o
b
s
w
ﬁ
f
c
d
a
o
i
m
C
T
y
b
f
f
r
C
T
A
T
a
R
1
1
1
1
1
1
1
1
1
1
228  
Li  et  al.22 indicated  that  there  is  a  greater  risk  for  hearing
oss  in  children  under  5  years  of  age.  Brock  et  al.,18 Simon
t  al.,29 and  Gunn  et  al.30 found  no  statistically  signiﬁcant
elationship  between  the  use  of  CDDP  and  age.
In  the  present  sample,  it  was  found  that  the  age  of  6
ears  at  the  time  of  cancer  diagnosis  imparted  a  2.7  times
igher  risk  for  hearing  loss  (p  =  0.02)  compared  with  children
6  years  of  age  at  diagnosis,  but  only  for  the  right  ear,  with
 tendency  for  the  left  ear  (OR  =  2.1;  p  =  0.08).  This  ﬁnding
ay  be  due  to  this  series  of  patients,  who  had  their  hearing
oss  concentrated  in  osteosarcoma  diagnoses,  more  often
stablished  in  adolescence  (Table  1).
The  present  study  found  no  statistically  signiﬁcant  rela-
ionship  for  gender;  however,  Yancey  et  al.28 reported  that
ender  and  cumulative  dose  are  the  most  important  clini-
al  markers  of  ototoxicity.  The  severity  of  ototoxicity  may
e  inversely  related  to  age  at  the  time  of  treatment,  and
ounger  children  have  greater  degrees  of  hearing  loss  after
reatment.28 Ondrey  et  al.31 believe  that  the  combination
f  these  two  treatments  (Rxt  +  QT)  will  be  the  best  can-
er  treatment  in  the  future;  however,  both  therapies  cause
totoxic  effects.
In  this  study,  the  sample  of  patients  undergoing  a  com-
ined  treatment  (Rxt  +  CDDP)  was  small  (n  =  10);  but  the
ame  degree  and  type  of  hearing  loss  was  found  in  patients
ho  underwent  chemotherapy  with  CDDP  without  Rxt.  This
nding  demonstrates  that,  in  this  study,  Rxt  was  not  a risk
actor  for  hearing  loss,  but  CDDP  was.
Considering  the  impact  of  hearing  loss,  even  if  sub-
linical,  on  the  linguistic,  pedagogical,  and  cognitive
evelopment  of  children  treated  for  cancer  in  childhood,32
nd  considering  also  that  studies  demonstrating  a  signiﬁcant
toprotective  effect  have  not  yet  been  published,33 the  most
mportant  tool  in  the  follow-up  of  these  patients  is  certainly
onitoring.34
onclusion
he  hearing  loss  identiﬁed  in  cancer  patients,  examined
ears  after  the  completion  of  treatment  was  sensorineural,
ilateral,  and  symmetrical,  and  predominantly  affected  the
requencies  of  4,  6,  and  8  kHz.
Chemotherapy  with  CDDP  was  demonstrated  to  be  a  risk
actor  for  acquisition  of  hearing  loss,  while  head  and  neck
adiation  therapy  was  not  decisive.
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